3 results
Approved WMORecruiting
The primary objective is reducing treatment-related morbidity and mortality without adversely impacting DFS in Ph+ ALL patients, classified as Standard Risk (SR) based on low minimal residual disease (MRD) at week 10-12 of therapy.Because there is…
Approved WMORecruiting
To investigate whether oral esketamine is non-inferior to ECT in achieving treatment response on depression severity in NTRD.
Approved WMORecruiting
The primary objective is to investigate whether pharmacological conditioning with S(+)-ketamine compared to pharmacological conditioning with placebo medication reduces pain sensitivity in patients with FMS.